Gout Treatment Insurance Denied? How to Appeal

Gout is the most common inflammatory arthritis in the United States, affecting more than 9 million Americans. Characterized by deposition of monosodium urate crystals in joints and soft tissues, it causes acute flares of severe joint pain (most commonly the first metatarsophalangeal joint, ICD-10 M10.071/M10.072) and, if undertreated, can progress to chronic tophaceous gout (ICD-10 M1A.079) with joint destruction and renal involvement. Despite being a well-understood metabolic condition with proven treatment options, insurance denials for gout medications are surprisingly frequent — particularly for advanced urate-lowering therapies like pegloticase (Krystexxa) and febuxostat (Uloric), and even for colchicine. Here is what you need to know to appeal effectively.

Why Insurers Deny Gout Treatment

Colchicine brand-name denials and formulary restrictions. Colchicine has been used to treat gout for centuries, but brand-name formulations (Colcrys, Mitigare) became expensive following FDA approval and market exclusivity in 2009. Insurers frequently deny brand-name colchicine or require step therapy to generic alternatives. However, when a prescriber documents a clinical reason to prefer a specific formulation, step therapy override requests under state step therapy laws may apply.

Febuxostat denials citing allopurinol preference. Allopurinol is the first-line urate-lowering therapy (ULT) in the 2020 ACR (American College of Rheumatology) Guideline for the Management of Gout. Insurers routinely require documented failure of allopurinol before approving febuxostat, which is reasonable for most patients. However, when a patient has allopurinol hypersensitivity (ICD-10 T39.1), chronic kidney disease that limits allopurinol tolerability, or documented allopurinol failure at maximum tolerated doses, the step therapy requirement should be waivable with physician documentation.

Pegloticase (Krystexxa) denials — most expensive and most challenged. Pegloticase is approved by the FDA for treatment of chronic refractory gout in adults who have failed conventional ULT. It is the most expensive gout treatment and the most frequently denied. Insurers require documentation of: serum urate above 6 mg/dL despite maximum conventional ULT, tophaceous gout or frequent flares (typically 3 or more per year) causing functional impairment, and failure of both allopurinol and febuxostat. The 2020 ACR gout guidelines and the ACR's Pegloticase recommendations are the controlling clinical authority.

IL-1 inhibitor denials for acute gout flare treatment. Canakinumab (Ilaris) and anakinra (Kineret) are used off-label or under FDA approval for acute gout flares refractory to standard therapy (colchicine, NSAIDs, corticosteroids) in patients with contraindications to first-line agents. Insurers frequently deny these as not medically necessary or experimental, citing lack of on-label FDA approval for gout (for anakinra) or high cost (for canakinumab). Documentation of contraindications to standard agents and prior failed treatment is essential.

Denial of monitoring labs and urate level testing. The 2020 ACR gout guidelines recommend regular serum urate monitoring to a treat-to-target goal of <6 mg/dL (or <5 mg/dL in patients with tophi). Insurers sometimes deny repeated urate testing as excessive, failing to recognize that treat-to-target urate monitoring is the standard of care in gout management.

How to Appeal a Gout Treatment Denial

Step 1: Identify the Denial Category

Determine whether the denial is based on a formulary/step therapy rule, a medical necessity determination, or a Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization failure. Your appeal strategy differs significantly depending on the denial basis. For pegloticase denials, which are the most complex, the appeal must address each FDA-approved indication criterion explicitly.

Step 2: Obtain Documentation of Treatment History and Current Disease Burden

Your rheumatologist should provide a letter documenting: current serum urate level, frequency of acute flares in the past year with dates, presence of tophi (with imaging or physical examination documentation), existing comorbidities affecting drug choice (CKD stage for allopurinol dosing under 2020 ACR guidance, cardiovascular risk factors), prior ULT trials with doses and duration, and the reason the requested agent is medically necessary given that history.

Step 3: Cite the 2020 ACR Gout Management Guideline

The 2020 ACR Guideline for the Management of Gout (published in Arthritis and Rheumatology) is the controlling clinical authority for gout treatment decisions. It provides specific recommendations on: treat-to-target ULT strategy, first-line ULT choice (allopurinol), indications for switching to febuxostat, and criteria for pegloticase use in refractory gout. Print and include the relevant guideline excerpts with your appeal.

Step 4: Request Peer-to-Peer Review

Your rheumatologist should request a peer-to-peer review with the insurer's medical reviewer. This is particularly effective for pegloticase denials, where your rheumatologist can walk through the ACR criteria for refractory gout, present the serum urate trends showing failure of prior ULT, and demonstrate that the patient's clinical picture meets the FDA-approved indication for pegloticase.

Step 5: Invoke State Step Therapy Override Law

If the denial involves step therapy for febuxostat or a brand-name colchicine formulation, check whether your state has enacted a step therapy override law. Most states (over 30 as of 2025) have enacted step therapy protections requiring insurers to grant step therapy exceptions when: the preferred drug is contraindicated, the patient has tried and failed the preferred drug, or the treating physician documents that the preferred drug is clinically inappropriate for the individual patient.

Step 6: Request External Independent Review

If the internal appeal is denied, request an independent external review. Pegloticase denials in patients with documented refractory gout and ACR criteria met are frequently overturned at external review, because the treating rheumatologist's documentation of prior ULT failure and functional impairment from tophaceous gout aligns with the ACR guideline criteria that independent reviewers apply.

What to Include in Your Gout Appeal

• Rheumatologist's letter of medical necessity with serum urate levels, flare frequency documentation, tophi documentation (physical exam or imaging), and prior ULT trial history — with doses, duration, and reason for failure or intolerance
• 2020 ACR Guideline for Management of Gout excerpts, specifically the recommendations applicable to the treatment being denied — with the relevant recommendation text highlighted
• Serum urate level history (the last 6–12 months of laboratory values) demonstrating failure to achieve the ACR target of <6 mg/dL despite prior ULT
• For pegloticase appeals: documentation that the patient meets all FDA-approved criteria for pegloticase — refractory gout with serum urate >6 mg/dL, frequent flares or tophaceous disease, and failure of conventional ULT at appropriate doses
• State step therapy override law documentation, if applicable, with the statutory citation and the physician's written attestation meeting the override criteria

Fight Back With ClaimBack

Gout treatment denials — particularly for pegloticase and febuxostat — are consistently overturned when the appeal presents the rheumatologist's documentation of treatment history, current urate levels, and disease burden alongside the 2020 ACR guideline criteria that support the requested treatment. Tophi can destroy joints, and hyperuricemia is associated with serious cardiovascular and renal consequences — these are not quality-of-life disputes, but medically necessary treatment appeals. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal